Pulmonary arterial hypertension crisis caused by ketamine administration during transcatheter occlusion for ventricular septal defect in children with congenital heart diseases: a report of 2 cases

2010 ◽  
Vol 30 (10) ◽  
pp. 1160-1160
Author(s):  
Zhu-hua ZHANG ◽  
Shui-xiang YIN ◽  
Xiao-qiao LIU ◽  
Hua FANG ◽  
Jian-ping ZHANG
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Ventricular Septal Defect ◽  
Arterial Hypertension ◽  
Congenital Heart ◽  
Septal Defect ◽  
Heart Diseases ◽  
Congenital Heart Diseases ◽  
Transcatheter Occlusion ◽  
Pulmonary Arterial

Pulmonary arterial hypertension associated with congenital heart diseases

ESC CardioMed ◽  
2018 ◽  
pp. 2537-2540
Author(s):  
Margarita Brida ◽  
Gerhard-Paul Diller ◽  
Michael A. Gatzoulis
Keyword(s):  
Congenital Heart Disease ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Congenital Heart ◽  
Heart Diseases ◽  
Congenital Heart Diseases ◽  
Defect Closure ◽  
Eisenmenger Syndrome ◽  
Targeting Therapy ◽  
Pulmonary Arterial

Pulmonary arterial hypertension (PAH) is commonly associated with congenital heart disease (CHD) and relates to the type of the underlying defects and repair strategies. Large pulmonary shunts may develop PAH if untreated or repaired late. PAH, when present, markedly increases morbidity and mortality in CHD patients. Significant progress has been made for patients with Eisenmenger syndrome in pathophysiology, prognostication, and disease-targeting therapy. Patients with PAH-CHD and left-to-right shunting may benefit from late defect closure if pulmonary vascular resistance is normal or near normal. Patients with PAH-CHD and coincidental defects and also patients with previous repair of CHD should be managed as those with idiopathic PAH. All patients with PAH-CHD should be cared for at expert centres and those with Eisenmenger syndrome benefit from a proactive disease-targeting therapy approach. More research in this growing cardiovascular field is clearly warranted.

Pulmonary arterial hypertension associated with congenital heart diseases

ESC CardioMed ◽  
2018 ◽  
pp. 2537-2540
Author(s):  
Margarita Brida ◽  
Gerhard-Paul Diller ◽  
Michael A. Gatzoulis
Keyword(s):  
Congenital Heart Disease ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Congenital Heart ◽  
Heart Diseases ◽  
Congenital Heart Diseases ◽  
Defect Closure ◽  
Eisenmenger Syndrome ◽  
Targeting Therapy ◽  
Pulmonary Arterial

Pulmonary arterial hypertension (PAH) is commonly associated with congenital heart disease (CHD) and relates to the type of the underlying defects and repair strategies. Large pulmonary shunts may develop PAH if untreated or repaired late. PAH, when present, markedly increases morbidity and mortality in CHD patients. Significant progress has been made for patients with Eisenmenger syndrome in pathophysiology, prognostication, and disease-targeting therapy. Patients with PAH-CHD and left-to-right shunting may benefit from late defect closure if pulmonary vascular resistance is normal or near normal. Patients with PAH-CHD and coincidental defects and also patients with previous repair of CHD should be managed as those with idiopathic PAH. All patients with PAH-CHD should be cared for at expert centres and those with Eisenmenger syndrome benefit from a proactive disease-targeting therapy approach. More research in this growing cardiovascular field is clearly warranted.

Sign in / Sign up

Export Citation Format

Share Document